Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.47 |
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL13584450 | 0.81 | HTR2C (0.54) | HTR6HTR2CHTR2AHTR7DRD2 | |
| SCHEMBL6816705 | 0.76 | MET (0.45) | HTR6HTR2CCCNT1CDK9DRD2 | |
| Hydrochloric Acid SCHEMBL29882492 | 0.75 | HTR6 (0.50) | HTR6HTR2CHTR2AHTR7CCNT1 | |
| SCHEMBL5321082 | 0.75 | HTR6 (0.50) | HTR6HTR2CHTR2AHTR7CCNT1 | |
| SCHEMBL1513540 | 0.75 | HTR6 (0.50) | HTR6HTR2CHTR2AHTR7CCNT1 | |
| SCHEMBL5093538 | 0.75 | HTR6 (0.45) | HTR6HTR2CHTR2AHTR7CCNT1 | |
| SCHEMBL5845143 | 0.74 | HTR2C (0.65) | HTR6HTR2CHTR2AHTR7DRD2 | |
| SCHEMBL3434588 | 0.73 | HTR6 (0.52) | HTR6HTR2CHTR2AHTR7CCNT1 | |
| SCHEMBL8276239 | 0.73 | HTR6 (0.55) | HTR6HTR2CHTR2AHTR7CCNT1 | |
| SCHEMBL3435567 | 0.73 | HTR6 (0.49) | HTR6HTR2CHTR2AHTR7CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | HTR6 863/4885HTR2C 1211/4885HTR2A 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.